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OsteosarcomaDeregulated microRNAs and their roles in cancer development have attracted much attention. Although
miR-133a has been shown to be important in osteogenesis, its roles in osteosarcoma carcinogenesis and pro-
gression remain unknown. Hence, we focused on the expression and mechanisms of miR-133a in osteosarco-
ma development in this study. We found that miR-133a was downregulated in osteosarcoma cell lines and
primary human osteosarcoma tissues, and its decrease was signiﬁcantly correlated with tumor progression
and prognosis of the patients. Functional studies revealed that restoration of miR-133a could reduce cell pro-
liferation, promote cell apoptosis, and suppress tumorigenicity in osteosarcoma cell lines. Furthermore, bio-
informatic prediction and experimental validation were applied to identify target genes of miR-133a, and the
results revealed that the anti-tumor effect of miR-133a was probably due to targeting and repressing of
Bcl-xL and Mcl-1 expression. Taken together, our data elucidate the roles of miR-133a in osteosarcoma path-
ogenesis and implicate its potential in cancer therapy.
Crown Copyright © 2013 Published by Elsevier Inc. All rights reserved.Introduction
MicroRNAs (miRNAs) are an abundant class of 17–25 nucleotide
small noncoding RNAs. They posttranscriptionally regulate gene expres-
sion through binding to the 3′ untranslated regions (3′UTR) of target
mRNAs. Since the initial observation, about 1000 miRNA sequences
have been determined in mammals [1], but their detailed roles in
physiology and pathology still need investigation. Recently, growing
evidences have suggested that miRNAs participate in the regulation of
diverse biological processes [2], and their deregulation or dysfunction
plays critical roles in cancer development and clinical outcomes of cancer
patients [3]. However, evaluating the deregulated miRNAs and their
roles in cancer development, especially in osteosarcoma, is still an
ongoing process [4].
Osteosarcoma is themost common type of humanprimarymalignant
bone tumor characterized by an aggressive clinical course [5]. It usually
develops in children and young adults. Themechanisms that orchestrateerms of the Creative Commons
which permits non-commercial
d the original author and source
ics, Changhai Hospital, Second
hai 200433, China. Fax: +86
13 Published by Elsevier Inc. All righthe multiple oncogenic insults required for osteosarcoma carcinogenesis
and progression are still largely unclear. To date, deregulated miRNAs
and their roles in osteosarcomadevelopment have attractedmuch atten-
tion. Some of them, including miR-31, miR-34, miR-20a, miR-140 and
miR-143, have been reported to participate in the initiation and progres-
sion of osteosarcoma and modulate the biological properties of cancer
cells [6–15]. However, the detailed roles of miRNAs in cancer biology,
especially in osteosarcoma, still need to be further investigated.
miR-133a has been recognized as a muscle speciﬁc miRNA which
may regulate myoblast differentiation and participate in myogenic
and heart diseases [16–18]. And recently, miR-133a is also reported
to be an important regulator in osteogenesis, as its expression is
downregulated in bone morphogenetic protein (BMP)-induced osteo-
genesis and it can target and suppress RunX2 expression to inhibit
osteoblast differentiation [19]. But whether miR-133a is deregulated
in osteosarcoma and its potential roles in osteosarcoma carcinogenesis
and progression are still unknown.
In this study, we have taken efforts to explore the potential roles of
miR-133a in osteosarcoma development. The expression of miR-133a
in clinically resected human osteosarcoma tissues was evaluated, and
the correlation betweenmiR-133a deregulation and osteosarcoma pro-
gression was analyzed. Furthermore, the roles of miR-133a in osteosar-
coma development and the underlying mechanisms were investigated.
Our data indicate the roles ofmiR-133a in the control of cell growth and
apoptosis in osteosarcoma, and suggest the potential therapeutic appli-
cation of miR-133a for osteosarcoma patients.ts reserved.
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Patients and osteosarcoma tissues
Surgically resected paired osteosarcoma tumor tissues and adjacent
normal tissues used in qRT-PCR and Western blot were collected from
92 primary osteosarcoma patients who received operations between
2006 and 2009 at Changhai Hospital (Shanghai, China), and the detailed
information of these patients were shown in Supplementary Table 1.
Surgically removed tissues were quickly frozen in liquid nitrogen until
analysis. All samples were collected with the informed consents of the
patients and the experiments were approved by the ethics committee
of Second Military Medical University, Shanghai, China. The investiga-
tions were conducted according to the Declaration of Helsinki
principles.
RNA extraction and qRT-PCR
Total RNA, including miRNA, was extracted using miRNeasy kit
(Qiagen) according to the manufacturer's instructions. To detect
miRNA expression, real-time quantitative RT-PCR (qRT-PCR) analysis
was performed using LightCycler (Roche) and SYBR RT-PCR kit
(Takara). For miRNA analysis, stem-loop RT primers for miR-133a
were 5′-GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC GCA CTG
GAT ACG ACC AGC T-3′, and quantitative PCR primers were 5′-TTT
GGT CCC CTT CAA CC-3′ (forward) and 5′-GTG CAG GGT CCG AGG
T-3′ (reverse) [15]. Primers for detecting internal control U6 expres-
sion were described previously [15]. The relative expression level of
miR-133a was normalized to that of internal control U6 by using
2−ΔΔCt cycle threshold method [20].
Cell culture and transfection
Human normal osteoblastic cell line hFOB 1.19, and human osteo-
sarcoma cell lines MG63 and U2OS were obtained, cultured, seeded,
and transfected as we described previously [15]. In brief, 5 × 103 or
5 × 105 cells were seeded into each well of 96-well plate or 6-well
plate respectively and incubated overnight, then transfected with
miRNAmimics or inhibitor at a ﬁnal concentration of 20 nMor 50 nM re-
spectively using INTERFERin transfection reagent (Polyplus-transfection)
following the manufacturer's instructions. Negative control (NC) RNA or
miR-133a mimics, and negative control inhibitor or miR-133a inhibitor
were all 2′-O-methyl modiﬁed to improve RNA stability and synthesized
by GenePharma (Shanghai, China). siRNAs targeting human Bcl-xL were
5′-GGU AUU GGU GAG UCG GAU CdTdT-3′ and 5′-GAU CCG ACU CAC
CAA UAC CdTdT-3′; siRNAs targeting human Mcl-1 were 5′-GAA ACG
CGG UAA UCG GAC UdTdT-3′ and 5′-AGU CCG AUU ACC GCG UUU
CdTdT-3′.
Analysis of cell proliferation in vitro
The in vitro cell proliferation ofMG63 or U2OS cells transfectedwith
NC ormiR-133awasmeasured using theMTTmethod [15]. Brieﬂy, cells
were seeded into 96-well plates and transfected. In the indicated time
periods, spent medium was replaced with fresh medium containing
0.5 mg/ml MTT. Cells were then incubated at 37 °C for 4 h and resolved
by DMSO (Sigma). The absorbance was measured at 570 nm.
Detection of apoptosis
Osteosarcoma MG63 or U2OS cells were transfected with NC or
miR-133a mimics respectively. At 48 h post transfection, spent cell
culture medium was replaced with serum free DMEM and placed in
1% oxygen incubator. In the indicated time periods post serum depri-
vation, cells were harvested, washed, resuspended in the staining
buffer, and examined with Vybrant Apoptosis Assay kit (Invitrogen).Stained cells were detected by FACSCalibur and data were analyzed
with CellQuest software (both from Becton Dickinson). The Annexin
V-positive cells were regarded as apoptotic cells.
Tumorigenicity assay in nude mice
All experiments involving animals were undertaken in accordance
with the National Institute of Health Guide for the Care and Use of
Laboratory Animals, with the approval of the Scientiﬁc Investigation
Board of Second Military Medical University, Shanghai, China. The tu-
morigenicity assay was performed as reported previously [15,21,22].
In detail, NC or miR-133a transfected osteosarcoma MG63 or U2OS
cells (1 × 106) were suspended in 0.1 ml PBS and then injected sub-
cutaneously into either side of the posterior ﬂank of the same BALB/c
athymic nude mice at 4 wk of age. Tumor growth was measured
using caliper daily, and tumor volume was calculated according to
the formula: volume = length × width2 × 0.5.
3′UTR luciferase reporter assay
The human B-cell lymphoma-extra large (Bcl-xL) and myeloid cell
leukemia-1 (Mcl-1) 3′UTR luciferase reporter constructs and these
constructs with miR-133a target site deletion were made as we de-
scribed previously [15]. All constructs were conﬁrmed by DNA se-
quencing. Luciferase reporter assay was performed as reported [15].
Brieﬂy, at 36 h post transfection, luciferase activities were detected
using Dual-Luciferase Reporter Assay System (Promega) following
the manufacturer's instructions. Data were normalized by dividing
Fireﬂy luciferase activity with that of Renilla luciferase.
Western blot
Cells and grinded human tissues were lysed using M-PER Protein
Extraction Reagent (Pierce) supplemented with protease inhibitor
cocktail (Calbiochem). Protein concentrations of the extractsweremea-
sured with BCA assay (Pierce) and equalized with the extraction re-
agent. Equal amounts of the extracts were loaded and subjected to
SDS-PAGE, transferred onto nitrocellulose membranes, and then blot-
ted as reported [15]. Antibodies speciﬁc to Bcl-xL, Mcl-1, β-actin, and
horseradish peroxidase-coupled secondary antibodies were purchased
from Cell Signaling Technology. Densitometric analysis was done with
Labworks Image Acquisition and Analysis Software (UVP, Upland, CA).
The background was subtracted, and the signals of the detected bands
were normalized to the amount of loading control β-actin band.
Statistical analysis
Data are shown as mean ± s.d. Statistical comparisons between
groups were analyzed using Student's t-test and a two-tailed
p b 0.05 was considered to indicate statistical signiﬁcance. The corre-
lation between miR-133a expression and clinical osteosarcoma stages
was analyzed using Spearman's rank correlation coefﬁcient assay in
SPSS 17.0. Analysis of overall survival in osteosarcoma patients was
performed using log-rank test in SPSS 17.0. The correlation between
miR-133a expression and Bcl-xL or Mcl-1 protein levels was analyzed
using Pearson's correlation coefﬁcient assay in SPSS 17.0.
Results
miR-133a is downregulated in osteosarcoma
In order to investigate the roles of miR-133a in human osteosarco-
ma development, we compared miR-133a expression in human
normal osteoblastic cell line hFOB 1.19 with that in human osteosar-
coma cell lines MG63 and U2OS by real-time qRT-PCR. And miR-133a
expression was signiﬁcantly decreased in osteosarcoma MG63 and
222 F. Ji et al. / Bone 56 (2013) 220–226U2OS cells (Fig. 1A). Furthermore, in the 92 pairs of human primary
osteosarcoma tumor and adjacent normal tissue samples, miR-133a
expression was signiﬁcantly suppressed in tumor tissues as compared
to that in adjacent normal tissues (Fig. 1B). These results suggest that
miR-133a is downregulated in osteosarcoma cells, which might be in-
volved in human osteosarcoma development.Downregulated miR-133a is correlated with osteosarcoma progression
and prognosis
Wenext investigatedwhether the downregulation of miR-133awas
correlated with osteosarcoma progression. By using Spearman's rank
correlation assay, we found that miR-133a expression in tumor tissues
was signiﬁcantly reverse-correlated with osteosarcoma clinical tumor
stages in tested human samples (Fig. 2A). These results suggest that de-
creased miR-133a expression may participate in the progression of os-
teosarcoma. Furthermore, the Kaplan–Meier survival analysis also
revealed that low miR-133a expression in tumor tissues was signiﬁ-
cantly correlated with the reduced overall survival of osteosarcoma pa-
tients (Fig. 2B). Together, these results indicate the important roles of
miR-133a in both progression and prognosis of osteosarcoma.Fig. 1. miR-133a is downregulated in osteosarcoma cell lines and clinical human oste-
osarcoma tissues. miR-133a expression was examined in osteosarcoma cell lines (A),
or 92 paired clinical human osteosarcoma tissues and adjacent normal tissues (B) as
indicated using qRT-PCR. Expression of miR-133a was normalized to that of U6 in
each sample. Data are shown as mean ± s.d. (n = 4) in cell lines (A), or as the hori-
zontal lines (median), the boxes (interquartile range), and the whiskers (2.5th and
97.5th percentiles) in human samples (B). **, p b 0.01.
Fig. 2. miR-133a downregulation is correlated with osteosarcoma progression and
prognosis of the patients. (A) In the 92 human osteosarcoma tissues, correlation be-
tween miR-133a expression and tumor stages I to III was analyzed by Spearman's
rank correlation assay in SPSS 17.0 with the r and p values indicated. Data are shown
as in Fig. 1A of miR-133a expression in each stage. (B) Shown is the Kaplan–Meier sur-
vival curve of overall survival in the 92 osteosarcoma patients according to miR-133a
level in tumor tissues. The 5-year overall survival rate of the 92 patients was 41%.
The median value of miR-133a expression in these tumor samples was chosen as the
cut-off. Data were analyzed by SPSS 17.0 with p value indicated.miR-133a reduces cell proliferation, promotes cell apoptosis, and suppresses
tumorigenicity
Decreased expression of miR-133a in tumor samples inspired us
to investigate whether miR-133a functions as a tumor suppressor in
osteosarcoma. In MG63 and U2OS cells, transfection of miR-133a
mimics signiﬁcantly restored intracellular miR-133a expression
(Supplementary Fig. 1A), and restoration of miR-133a reduced cell
proliferation in both osteosarcoma cell lines (Fig. 3A). Furthermore,
miR-133a restoration promoted cell apoptosis upon serum depriva-
tion and hypoxia in the osteosarcoma cells (Fig. 3B). These results
demonstrate that miR-133a inhibits osteosarcoma growth in vitro.
Next, an in vivomodel was applied to evaluate the effect ofmiR-133a
restoration on tumorigenicity. In miR-133a transfected MG63 and U2OS
cells, exogenous miR-133a expression could be maintained for 5 to
10 days in osteosarcoma cells after inoculation in nude mice (Supple-
mentary Fig. 1B). Notably, miR-133a mimic transfected osteosarcoma
MG63 and U2OS cells revealed delayed tumor formation and dramatic
reduction of tumor sizes as compared to that of the negative control
transfectants (Fig. 3C). As exogenous miR-133a expression could be
maintained only in the early period post osteosarcoma inoculation, we
presume that the proliferation-inhibiting and apoptosis-promoting
Fig. 3. miR-133a reduces cell proliferation, promotes cell apoptosis, and suppresses tumorigenicity. (A) Osteosarcoma MG63 or U2OS cells were transfected with control RNA or
miR-133a mimics as indicated. Cell proliferation was measured in the indicated time periods post transfection using MTT assay. (B) MG63 or U2OS cells were transfected as in
(A) and treated with serum deprivation and hypoxia for 48 h. Cells were stained with PI and Annexin V, and analyzed using FACS. (C) Control RNA or miR-133a mimic transfected
MG63 or U2OS cells were injected subcutaneously into the either side of the posterior ﬂank of the same nude mice respectively. Tumor growth was measured and the curves were
shown as indicated. Data are shown as mean ± s.d. (n = 4) or presented separately of one representative experiment. Similar results were obtained in three independent experiments.
*, p b 0.05; **, p b 0.01.
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which in turn results in the observed suppressed tumorigenicity of
miR-133a transfectants. Together, these results further suggest the
tumor suppressive effect of miR-133a on osteosarcoma.
As expression of miR-133a is relatively higher in human normal
osteoblast cell line hFOB 1.19, we further evaluated the effects of
miR-133a inhibition on cell proliferation and apoptosis in hFOB 1.19.
As shown in Supplementary Fig. 2, transfection of miR-133a inhibitor
signiﬁcantly inhibited miR-133a expression, and miR-133a inhibition
enhanced cell proliferation as well as inhibited the serum deprivation
and hypoxia induced cell apoptosis. These results validated the roles
of miR-133a in cell proliferation and apoptosis.
miR-133a targets Bcl-xL and Mcl-1
In order to further investigate the molecular basis for the apoptosis
promoting effect of miR-133a on osteosarcoma, we next worked on
identifying the molecular targets of miR-133a. The predicted targetgenes of miR-133a in TargetScan database (http://www.targetscan.
org) were all retrieved and subjected to the enrichment analysis of
cell signaling pathways using Kyoto Encyclopedia of Genes and Ge-
nomes (KEGG) pathway database (http://www.genome.jp/kegg/) [3].
We found that KEGG pathway “pathway in cancer”was themost signif-
icantly enriched by the predicted targets of miR-133a (p = 0.001)
(Supplementary Fig. 3 and Table 2), suggesting that miR-133a may
play an important role in the inhibition of osteosarcoma intracellular
signaling. Interestingly, to elucidate the apoptosis promoting role of
miR-133a in osteosarcoma cells, we observed that Bcl-xL and Mcl-1,
which are well-accepted anti-apoptotic molecules in osteosarcoma
[23,24], were both potential targets of miR-133a (Fig. 4A).
Taken together the previous reports which determined that both
Bcl-xL and Mcl-1 were upregulated in osteosarcoma and exerted the
anti-apoptotic and pro-survival function of osteosarcoma cells [23,24],
we presumed that miR-133a may promote cell apoptosis of osteosarco-
ma through targeting Bcl-xL and Mcl-1 expression. To verify whether
Bcl-xL and Mcl-1 are direct targets of miR-133a, a dual-luciferase
Fig. 4. Anti-apoptotic Bcl-xL and Mcl-1 are directly targeted by miR-133a. (A) Se-
quence alignment of miR-133a and its predictive target sites in 3′UTR of Bcl-xL and
Mcl-1 was shown as indicated, and the data were downloaded from TargetScan
(http://www.targetscan.org). (B) MG63 cells were co-transfected with Bcl-xL or
Mcl-1 3′UTR Fireﬂy luciferase reporter plasmid, or miR-133a target sites deleted re-
porter construct, together with Renilla plasmids, control RNA or miR-133a mimics as
indicated. After 36 h, Fireﬂy luciferase activity was measured and normalized by
Renilla luciferase activity. (C) MG63 and U2OS cells were transfected with control
RNA or miR-133a mimics. Expression of Bcl-xL, Mcl-1, and internal control β-actin
was detected by Western blot. Data are shown as mean ± s.d. (n = 4) of one
representative experiment. Similar results were performed in three independent
experiments. **, p b 0.01.
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erase reporter plasmids containing 3′UTR of human Bcl-xL or Mcl-1, or
bearing deletions of the putative miR-133a target sites. As shown inFig. 4B, co-transfection of miR-133a suppressed the luciferase activity
of the reporter containing wildtype Bcl-xL or Mcl-1 3′UTR sequence,
but failed to inhibit that of the target site deleted construct by
dual-luciferase reporter assay. These data suggest that miR-133a can di-
rectly target the 3′UTR sequences of both Bcl-xL andMcl-1. Additionally,
in osteosarcomaMG63 and U2OS cells, endogenous expression of Bcl-xL
and Mcl-1 protein level was suppressed by miR-133a transfection
(Fig. 4C); while in hFOB 1.19 cells, Bcl-xL and Mcl-1 expression was en-
hanced by miR-133a inhibition (Supplementary Fig. 2D). These results
demonstrate that endogenous Bcl-xL and Mcl-1 expression is directly
targeted and regulated by miR-133a and suggest that miR-133a
may exert its pro-apoptotic function via inhibiting Bcl-xL and Mcl-1
expression.
We further compared Bcl-xL and Mcl-1 protein expression in
human normal osteoblastic hFOB 1.19 cells and osteosarcoma MG63
and U2OS cells, as miR-133a was observed to be downregulated in os-
teosarcoma cells above. As shown in Fig. 5A, Bcl-xL and Mcl-1 protein
expression was signiﬁcantly upregulated in osteosarcoma cells. Fur-
thermore, correlation between miR-133a level and the protein level
of Bcl-xL or Mcl-1 was next examined in primary human osteosarco-
ma tissues. By qRT-PCR and Western blot detection, as shown in
Fig. 5B, Pearson's correlation coefﬁcient assay suggested that Bcl-xL
and Mcl-1 expression was both inverse-correlated with miR-133a
expression in osteosarcoma tissues. These data further suggest that
miR-133a down-regulation may contribute to the overexpressed
Bcl-xL and Mcl-1 in osteosarcoma.
The pro-apoptotic effect of miR-133a may be through targeting Bcl-xL
and Mcl-1
To determine the roles of Bcl-xL and Mcl-1 in miR-133a-promoted
apoptosis, we assessed whether knockdown of the endogenous Bcl-xL
orMcl-1was able tomimic the effect ofmiR-133a restoration. Transfec-
tion of Bcl-xL or Mcl-1 siRNAs signiﬁcantly suppressed their expression
respectively (Fig. 6A), and promoted cell apoptosis upon serum depri-
vation and hypoxia in osteosarcoma cells (Fig. 6B). These data suggest
that the pro-apoptotic effect of miR-133a may be through inhibiting
its target genes Bcl-xL and Mcl-1.
Discussion
Osteosarcoma is the most common human primary malignant bone
tumor characterized by an aggressive clinical course. Thus, in recent
years, it has become one of the most promising ﬁelds to investigate mo-
lecular mechanisms contributing to osteosarcoma carcinogenesis and
progression, especially identiﬁcation and investigation of the deregulated
miRNAs in osteosarcoma development. Several deregulated miRNAs,
such as upregulated miR-21 and miR-140; downregulated miR-34,
miR-143, and miR-34 members, have been reported and remarked in
osteosarcoma development [4]. However, it is still an ongoing process
to elucidate new important deregulated miRNAs and their detailed
roles in cancer biology, especially in osteosarcoma carcinogenesis and
progression.
Here, we presented the downregulation of miR-133a in osteosarco-
ma and suggested the anti-tumor effect of miR-133a in osteosarcoma
pathogenesis. As previously reported, miR-133a expressionwas proved
to play an important role during osteoblast differentiation, by the ﬁnd-
ing that BMP2 treatment could decrease the expression of miR-133a
during osteoblast lineage commitment and osteogenesis [19]. Together
with our ﬁnding that miR-133a is further decreased in osteosarcoma,
we presume that miR-133a expression is decreased during osteoblast
commitment but further miR-133a decrease may contribute to osteo-
sarcoma development. In combination with previous reports revealing
the roles of miR-133a in some other types of cancer, such as bladder
cancer, esophagus cancer, and prostate cancer [25–27], we further con-
ﬁrmed that miR-133a might function as a tumor suppressor or an
Fig. 5. Correlation between miR-133a expression and Bcl-xL or Mcl-1 protein levels in
osteosarcoma. (A) Shown are the protein expression of Bcl-xL, Mcl-1, and internal con-
trol β-actin in human normal osteoblastic hFOB 1.19 cell line versus osteosarcoma
MG63 and U2OS cell lines detected by Western blot. (B) Expression of Bcl-xL and
Mcl-1 examined by Western blotting was densitometrically quantiﬁed and normalized
to β-actin expression. miR-133a expression was measured by qRT-PCR. Statistical anal-
ysis was performed using Pearson's correlation coefﬁcient assay in SPSS 17.0. miR-133a
expression and Bcl-xL or Mcl-1 protein levels were shown as standardized values. r and
p values were shown as indicated.
Fig. 6. Inhibition of Bcl-xL and Mcl-1 might be responsible for the tumor suppressive
effect of miR-133a. (A) MG63 cells were transfected with control RNA, Bcl-xL siRNA,
or Mcl-1 siRNA as indicated. After 48 h, expression of Bcl-xL, Mcl-1, and internal
control β-actin was detected by Western blot. (B) MG63 cells were transfected as in
(A) and treated with serum deprivation and hypoxia for 48 h. Cells were stained
with PI and Annexin V, and analyzed using FACS. Data are shown as representative
pictures. Similar results were performed in three independent experiments.
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miR-133a expression is decreased in all these types of cancer, but the
underlying mechanisms which mediate the downregulation of
miR-133a in cancer are still elusive. We have tried to ﬁgure out the
mechanisms responsible for miR-133a decrease in osteosarcoma. Two
miR-133a gene locus (has-miR-133a-1, Chr 18; and has-miR-133a-2,
Chr 20) was detected in osteosarcoma genome, and we found thatequal amounts of the two miR-133a genes were detected as compared
to those in thematched adjacent normal tissues (data not shown), thus
suggesting that the two miR-133a genes are less likely to be deleted in
osteosarcoma genome. Furthermore, we treated osteosarcoma MG63
and U2OS cells with DNA methylation inhibitor 5′-aza or HDAC inhibi-
tor TSA, and found that miR-133a expression is rarely changed (data
not shown), thus suggesting that miR-133a decrease in osteosarcoma
may be less likely to be mediated by the enhanced DNA methylation
or decreased histone acetylation. Hence, we presume that the mecha-
nisms responsible for miR-133a decrease may be complicated or even
the accumulation of various factors, such as epigenetic modiﬁcations,
transcriptional factors, signaling cascades, andmiRNAdegrading routes.
We will keep on investigating this issue in our future work.
Recently, identiﬁcation of the molecular biomarkers correlating
with progression and prognosis of cancer patients has attracted much
attention. We presented here that the down-regulated miR-133a ex-
pression in osteosarcoma tissues was correlated with the cancer stages
and overall survival of osteosarcoma patients, thus suggesting the po-
tential roles of miR-133a in osteosarcoma development and outlining
a potential biomarker of prognosis prediction for these patients.
226 F. Ji et al. / Bone 56 (2013) 220–226Additionally, previous reports have showed that the expression of
some coding genes, including Bcl-xL, is also correlated with overall sur-
vival of osteosarcoma patients [23]. Hence, combined detection of the
deregulatedmiRNAs and coding genes, includingmiR-133a,may be valu-
able to predict the prognosis of osteosarcoma patients more accurately.
The anti-tumor effect of miR-133a in osteosarcoma is validated both
in vitro and in vivo. Restoration of miR-133a expression signiﬁcantly
reduces cell proliferation, promotes cell apoptosis, and suppresses tu-
morigenicity. Together with the reports that Bcl-xL and Mcl-1 are
both involved in the progression of osteosarcoma, our ﬁndings lead to
the thoughts that development of small molecule inhibitors to Bcl-2
family members may bear considerable potential for the targeted
therapy of osteosarcoma patients, especially for those who respond
poorly to radiotherapy or chemotherapy.
Human important anti-apoptotic moleculars Bcl-xL and Mcl-1 are
identiﬁed to be new direct targets of miR-133a in osteosarcoma,
suggesting that miR-133a may exert its pro-apoptotic function via
inhibiting Bcl-xL and Mcl-1 expression. Bcl-2 family members are
well-accepted to be directly involved in serum deprivation and hypoxia
induced apoptosis, especially that Bcl-xL and Mcl-1 can prevent mito-
chondrial cytochrome c release and subsequent caspase-9-dependent
cell death, by which inhibiting apoptosis signaling [28]. Together with
the result that miR-133a can repress Bcl-xL and Mcl-1 expression, the
effects ofmiR-133a on promotion of serum deprivation and hypoxia in-
duced apoptosis are suggested to be mediated by inhibition of Bcl-xL
and Mcl-1 expression. Previous reports also showed that human EGFR,
TAGLN2, and FSCN1 are molecular targets of miR-133a in other types
of cancer [25–27]. In combination with our data, cancer pathways
may be tightly regulated by miR-133a expression, and miR-133a may
be a new therapeutic target to repress cancer progression. Additionally,
as myogenic researches of miR-133a have determined its several other
targets [16–18], these results are consistent with current opinions that
a single miRNA can target multiple mRNAs, named “targetome”, to
modulate gene expression [29]. Hence, it is probable that we are still
far fromunveiling the last target ofmiR-133a, and someof these potential
targetsmaybe still unknown in osteosarcomadevelopment. According to
this presumption, interesting future works may be raised to identify the
entire roles of miR-133a in cancer development.
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